Adult

Co-amoxiclav

Warning

General Information

A penicillin and beta-lactamase inhibitor. Do NOT use if patient is allergic to penicillin.

Amoxicillin and clavulanic acid

Formulary antimicrobial: Use in accordance with Trust guidelines 

AWaRe antibiotic classification: 'Watch'. Use as per guidelines. All other indications to be discussed with Micro/ID.

For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).

Standard dose

  Oral co-amoxiclav Intravenous co-amoxiclav
Standard dose 

625mg TDS 

(Amoxicillin 500mg and clavulanic acid 125mg)

1.2g TDS

(Amoxicillin 1000mg and clavulanic acid 200mg)

 

Obesity

No dose adjustment required. 

Renal and Hepatic impairment

Renal impairment

eGFR (mL/min/1.73m2)

Oral

co-amoxiclav dose

Intravenous 

co-amoxiclav dose

30 or more

No 

adjustment

No adjustment
Less than 30 1.2g bd
HD/ HDF/ High Flux/ PD 1.2g bd. Dialysed

Note: The reference for this dosing information is Renal Drug Database and dosing is different to those in BNF and Summary of Product Characteristics.

 

Hepatic impairment

  • Contraindicated in history of jaundice/hepatic impairment due to amoxicillin/clavulanic acid 
  • Dose with caution in hepatic impairment and monitor hepatic function at regular intervals.
  • Signs and symptoms of hepatic injury can occur either during or shortly after the use of co-amoxiclav but in some cases may not become apparent until several weeks after treatment has ceased.
  • Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment.

References

  • Co-amoxiclav 500mg/125mg film-coated Tablets [online]. Manufacturer - Brown & Burk UK Ltd – last updated: 2022 Oct 27. Accessed via: www.emc.medicines.org.uk [Accessed 2022 Nov 29].
  • Co-amoxiclav 1000/200 mg Powder for Solution for Injection/Infusion [online]. Manufacturer - Esteve Pharmaceuticals (formerly Intrapharm Laboratories) – last updated: 2022 Jun 21. Accessed via: www.emc.medicines.org.uk [Accessed 2022 Nov 29].
  • The Renal Drug Database. Co-amoxiclav - last updated: 2019 Sep 9. Accessed via: https://renaldrugdatabase.com [Accessed 16/9/23].

Editorial Information

Last reviewed: 01 Sept 2023

Next review date: 01 Sept 2026

Author(s): AMST.